LSI Zeta invest in Solid IO

✨News flash!✨ LSI Zetas third investment! Solid IO is developing a patient-specific hashtag#tumor-on-chip platform that uses living tumor tissue to hashtag#predict how individual hashtag#cancer patients will respond to treatment. By recreating the tumor hashtag#microenvironment outside the body, the platform enables functional testing of therapies before they are administered to the patient. The company’s technology aims to improve treatment selection, particularly in hashtag#immuno-oncology, where hashtag#response rates vary significantly between patients. Ultimately, Solid IO seeks to reduce hashtag#trial-and-error in cancer care and bring truly hashtag#personalized medicine closer to clinical practice. In addition also providing a tool to accelerate drug hashtag#development and creating vast value in the unique data generated through the platform. We are looking forward to work with Heidi Haikala, Noora Hujala, Bassel Alsaed and the rest of the team.

Also happy to collaborate with fellow investors Nordic Science Investments (Alexandra Gylfe PhD), Baltic Sandbox, Leo Capital (Olga Balakina).

Listen to Noora Hujala here.